WEBVTT - Novo's Martin Holst Lange Talks New Weight Loss Shot

0:00:02.520 --> 0:00:12.400
<v Speaker 1>Bloomberg Audio Studios, podcasts, radio news Time Now for some

0:00:12.440 --> 0:00:12.960
<v Speaker 1>top calls.

0:00:12.960 --> 0:00:15.960
<v Speaker 2>The analyst actions that we are following. First up, Jeffries

0:00:16.000 --> 0:00:19.079
<v Speaker 2>cuts Deer to a Cell, saying the stock already reflects a.

0:00:19.079 --> 0:00:20.759
<v Speaker 1>Full recovery and farm demand.

0:00:21.040 --> 0:00:24.239
<v Speaker 2>The firm also warned that higher costs, trade uncertainty, and

0:00:24.320 --> 0:00:27.680
<v Speaker 2>heavy debt could hamper the company's recovery. Next up, well

0:00:27.680 --> 0:00:30.680
<v Speaker 2>as Fargo, they upgrade Alphabet Dubui, calling it an AI

0:00:30.760 --> 0:00:34.560
<v Speaker 2>winner with strengths and consumer data distribution and compute capacity.

0:00:34.600 --> 0:00:37.279
<v Speaker 2>Shares only up two tens and percent, And finally, Bank

0:00:37.320 --> 0:00:40.839
<v Speaker 2>of America downgrades General Mills, saying its recovery story is

0:00:40.880 --> 0:00:41.760
<v Speaker 2>not playing out.

0:00:42.040 --> 0:00:44.159
<v Speaker 1>The firm says hopes for a PET rebound.

0:00:44.360 --> 0:00:48.919
<v Speaker 2>Instead, her sales have stalled as shoppers pull back elsewhere.

0:00:48.960 --> 0:00:53.080
<v Speaker 2>Nover Noordous next Generation OPEC shot cagri Semma underperformed Eli

0:00:53.240 --> 0:00:56.080
<v Speaker 2>Lilly's to Zeppra Tide and a head to head trial.

0:00:56.400 --> 0:01:00.000
<v Speaker 2>Let's bring a nover Noordous Chief Scientific Scientific Officer Mark

0:01:00.080 --> 0:01:02.720
<v Speaker 2>and host Long on this. Martin, thank you so much

0:01:02.720 --> 0:01:05.200
<v Speaker 2>for joining us this morning. And I just want to

0:01:05.200 --> 0:01:08.160
<v Speaker 2>bring you a comment from a shareholder of nov Nordice

0:01:08.240 --> 0:01:11.600
<v Speaker 2>of global Health invest NOV notice this opportunity to make

0:01:11.640 --> 0:01:12.319
<v Speaker 2>a comeback in the.

0:01:12.319 --> 0:01:14.399
<v Speaker 1>Fight against Lily. This was it.

0:01:14.800 --> 0:01:17.280
<v Speaker 2>This obviously weekends them in a fight. What would be

0:01:17.360 --> 0:01:20.160
<v Speaker 2>your message to those who believe the same thing, who

0:01:20.160 --> 0:01:22.479
<v Speaker 2>have looked at this study and said, now this means

0:01:22.520 --> 0:01:27.800
<v Speaker 2>NOVO is falling even further behind Eli Lilly, I.

0:01:27.800 --> 0:01:31.440
<v Speaker 3>Would answer, it's been a few years since we designed

0:01:32.000 --> 0:01:35.720
<v Speaker 3>the redefined program, the program to show the weight loss

0:01:35.760 --> 0:01:40.440
<v Speaker 3>potential of caguisemma. We already last year learned that to

0:01:40.640 --> 0:01:44.440
<v Speaker 3>really see the true weight loss potential of cagurosemma, it

0:01:44.520 --> 0:01:48.640
<v Speaker 3>is a very powerful combination of two molecules. We need

0:01:48.680 --> 0:01:51.400
<v Speaker 3>to have what we call it this both titration algorithms

0:01:51.440 --> 0:01:55.640
<v Speaker 3>to really allow patients to tyitrate the very powerful treatment

0:01:55.720 --> 0:01:58.680
<v Speaker 3>in the way that they prefer. We could see from

0:01:58.720 --> 0:02:03.160
<v Speaker 3>the first study that that could be further optimized in

0:02:03.200 --> 0:02:06.880
<v Speaker 3>this setting. We could not manage to implement those learnings

0:02:06.880 --> 0:02:09.280
<v Speaker 3>in what we call redefined form, which is the study

0:02:09.280 --> 0:02:13.800
<v Speaker 3>that we discussed today, So the jury is still out

0:02:13.919 --> 0:02:18.120
<v Speaker 3>of what can caguissemma actually achieve. In the study that

0:02:18.160 --> 0:02:21.000
<v Speaker 3>read out today, we saw twenty three percent weight loss

0:02:21.040 --> 0:02:25.880
<v Speaker 3>with cagrissimma that is actually very substantial and it is

0:02:25.919 --> 0:02:29.240
<v Speaker 3>among the best weight losses that we've seen also amongst

0:02:29.680 --> 0:02:30.799
<v Speaker 3>the drugs in the market.

0:02:31.040 --> 0:02:33.440
<v Speaker 2>Right, of course, just sort of the shore point in

0:02:33.440 --> 0:02:36.160
<v Speaker 2>that if I can jump in Martin is just the

0:02:36.160 --> 0:02:38.520
<v Speaker 2>comparison to Lily, it will forever be there.

0:02:38.760 --> 0:02:42.000
<v Speaker 1>So what is the plan then to catch up with them?

0:02:42.320 --> 0:02:45.480
<v Speaker 3>Yeah, exactly. So, first of all, the twenty three percent

0:02:45.520 --> 0:02:47.880
<v Speaker 3>weight loss that we solved with cagris emma is in

0:02:47.919 --> 0:02:50.800
<v Speaker 3>line with what we've previously seen. The twenty five percent

0:02:50.880 --> 0:02:53.520
<v Speaker 3>which we saw with the comparative drug is actually the

0:02:53.560 --> 0:02:58.320
<v Speaker 3>best data that has been seen so far in similar trials,

0:02:58.639 --> 0:03:02.560
<v Speaker 3>which is a little bit surprised, but it stands alone

0:03:02.960 --> 0:03:07.360
<v Speaker 3>in terms of that twenty five percent. But we've also

0:03:07.440 --> 0:03:09.680
<v Speaker 3>taken a lot of learnings in terms of how we

0:03:09.720 --> 0:03:13.920
<v Speaker 3>can improve the titration for cagrisemma. We've implemented those learnings

0:03:14.000 --> 0:03:16.799
<v Speaker 3>in the study that's currently ongoing that started it is

0:03:16.800 --> 0:03:19.960
<v Speaker 3>called Redefine eleven and reguarded for the last year. That

0:03:20.360 --> 0:03:22.520
<v Speaker 3>only when we see those data do we know the

0:03:22.639 --> 0:03:27.280
<v Speaker 3>full weight loss potential of cagrosemma. Furthermore, we are initiating

0:03:27.919 --> 0:03:31.280
<v Speaker 3>during this year Phase three start is to investigate it

0:03:31.480 --> 0:03:34.760
<v Speaker 3>even higher doses of cagrisemma. And then obviously we have

0:03:35.040 --> 0:03:39.640
<v Speaker 3>our very competitive pipeline starting within agamside that starts phase

0:03:39.640 --> 0:03:43.000
<v Speaker 3>three this year, but also our two triagonist that is

0:03:43.040 --> 0:03:46.000
<v Speaker 3>currently in phases one and two. So I think from

0:03:46.080 --> 0:03:48.200
<v Speaker 3>a short but also a longer term perspective, we have

0:03:48.240 --> 0:03:50.560
<v Speaker 3>a very competitive portfolio and pipeline.

0:03:51.600 --> 0:03:55.280
<v Speaker 2>Martin, on that pipeline, you seem confident on it. You

0:03:55.360 --> 0:03:57.480
<v Speaker 2>would you like to see that bolstered by some m

0:03:57.560 --> 0:03:59.920
<v Speaker 2>and a by bringing in organic growth to the pipe

0:04:00.040 --> 0:04:00.480
<v Speaker 2>line too.

0:04:02.440 --> 0:04:04.760
<v Speaker 3>The way we think about this is that business is

0:04:04.760 --> 0:04:07.960
<v Speaker 3>a very complex disease, and obviously we want to have

0:04:08.040 --> 0:04:10.480
<v Speaker 3>drugs that provide the biggest weight loss, but we also

0:04:10.600 --> 0:04:13.320
<v Speaker 3>have want to have drugs that gives as few side

0:04:13.360 --> 0:04:15.560
<v Speaker 3>effects as possible. That we also have want to have

0:04:15.640 --> 0:04:19.920
<v Speaker 3>drugs that provide commobidities, and to an extent, in our

0:04:19.920 --> 0:04:22.640
<v Speaker 3>current portfolio we have all of that. We also have

0:04:22.880 --> 0:04:27.800
<v Speaker 3>the best in class all already on the market in

0:04:27.839 --> 0:04:32.560
<v Speaker 3>the US, and the Senate Game Site offering that is

0:04:32.560 --> 0:04:36.000
<v Speaker 3>starting phase three will have both a subconchaneous and an

0:04:36.040 --> 0:04:39.200
<v Speaker 3>awful all offering with what we be with market.

0:04:39.279 --> 0:04:41.919
<v Speaker 2>Why why within that did you not follow Lily with

0:04:41.960 --> 0:04:43.960
<v Speaker 2>the truer Zepra tide and develop a g LP one

0:04:44.040 --> 0:04:45.880
<v Speaker 2>g I P Why not go down that route when

0:04:45.960 --> 0:04:47.080
<v Speaker 2>so many other companies did.

0:04:50.080 --> 0:04:54.120
<v Speaker 3>We need to follow our philosophy. Where we do development,

0:04:54.200 --> 0:04:57.239
<v Speaker 3>we also want to we always want to see differentiated

0:04:57.320 --> 0:05:00.600
<v Speaker 3>weight loss potential or efficacy potential, but also the differentiated

0:05:00.640 --> 0:05:03.719
<v Speaker 3>safety and sol ability. We do believe that we will

0:05:03.760 --> 0:05:08.440
<v Speaker 3>see that when we see redefine eleven in terms of

0:05:08.520 --> 0:05:11.560
<v Speaker 3>weight loss CAKU SMA. But we also believe that we

0:05:11.600 --> 0:05:15.680
<v Speaker 3>have that potential for EMI cretin, which is another version

0:05:15.960 --> 0:05:21.320
<v Speaker 3>of addressing two biologies. So you mentioned GLP one g

0:05:21.400 --> 0:05:29.160
<v Speaker 3>ip senagamtide is GLP one plus sorry, Emlin. And then

0:05:29.160 --> 0:05:32.039
<v Speaker 3>we have what we call triagonist, which is basically the

0:05:32.160 --> 0:05:33.840
<v Speaker 3>next level.

0:05:34.560 --> 0:05:35.839
<v Speaker 1>We do again.

0:05:35.600 --> 0:05:38.039
<v Speaker 3>Believe that that is going to be a very competitive

0:05:38.120 --> 0:05:41.640
<v Speaker 3>offering individually but specifically as a portfolio.

0:05:41.800 --> 0:05:43.280
<v Speaker 2>Okay, Martin, we're going to have to leave it there.

0:05:43.320 --> 0:05:45.200
<v Speaker 2>Thank you so much for joining us today. That's never

0:05:45.320 --> 0:05:48.520
<v Speaker 2>not As Chief Scientificate Officer, Martin host Long